Australia markets open in 30 minutes

Evoke Pharma, Inc. (EV00.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.6250+0.0100 (+1.63%)
At close: 08:16AM CET
Full screen
Previous close0.6150
Open0.6250
Bid0.6200 x N/A
Ask0.6400 x N/A
Day's range0.6250 - 0.6250
52-week range0.5500 - 3.3400
Volume200
Avg. volume0
Market cap5.438M
Beta (5Y monthly)0.22
PE ratio (TTM)N/A
EPS (TTM)-2.1100
Earnings date19 Mar 2024 - 25 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Evoke Pharma Announces Closing of $7.5 Million Public Offering

    Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in FullSOLANA BEACH, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has closed an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for

  • GlobeNewswire

    Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

    SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has priced an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of up to $30 million, that includes initial upfront funding of approximatel

  • GlobeNewswire

    Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

    GIMOTI now holds four listed patents with coverage through 2029SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No. 11,813,231 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Th